ArticleThoracic cancer2022

Efficacy and safety of second-line chemotherapy for patients with advanced non-small cell lung cancer complicated by interstitial lung disease.

Kenji Otsuka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.